TPCW
SAGE

TD Private Client Wealth’s Sage Therapeutics SAGE Stock Holding History

TD Private Client Wealth’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23
Closed -$1.31K – 1237
2021
Q2 		$1.31K Buy
23
+3
+15% +$212 ﹤0.01% 1075
2021
Q1 		$1.5K Sell
20
-7
-26% -$574 ﹤0.01% 1024
2020
Q4 		$2.34K Buy
27
+12
+80% +$884 ﹤0.01% 950
2020
Q3 		$917 Buy
15
+8
+114% +$405 ﹤0.01% 971
2020
Q2 		$291 Sell
7
-9
-56% -$327 ﹤0.01% 1076
2020
Q1 		$460 Buy
16
+4
+33% +$232 ﹤0.01% 975
2019
Q4 		$866 Buy
+12
New +$1.48K ﹤0.01% 957

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TD Private Client Wealth's SAGE Position: Q3 2021 in Review

TD Private Client Wealth sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 23 shares — an estimated $1.31K sold.

TD Private Client Wealth first reported a position in SAGE in Q4 2019 and held it in 7 quarters. The position peaked at $2.34K in Q4 2020. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • TD Private Client Wealth reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • TD Private Client Wealth sold 23 Sage Therapeutics shares in Q3 2021, an estimated $1.31K.
  • TD Private Client Wealth first reported a position in Sage Therapeutics in Q4 2019 and held it in 7 quarters.
  • TD Private Client Wealth's Sage Therapeutics position peaked at $2.34K in Q4 2020.
  • 226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on TD Private Client Wealth's 13F filing for Q3 2021, filed 16 Aug 2024.